Add-on combination therapy with monoclonal antibodies: Implications for drug development.
Saved in:
| Title: | Add-on combination therapy with monoclonal antibodies: Implications for drug development. |
|---|---|
| Authors: | Cummings J; Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, Nevada, USA. Electronic address: jcummings@cnsinnovations.com., Burstein AH; Alzheimer's Drug Discovery Foundation (ADDF), New York, New York, USA., Fillit H; Alzheimer's Drug Discovery Foundation (ADDF), New York, New York, USA. |
| Source: | The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2025 Dec; Vol. 12 (10), pp. 100359. Date of Electronic Publication: 2025 Oct 27. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2426-0266 |
|---|---|
| DOI: | 10.1016/j.tjpad.2025.100359 |
